Ebola Virus Disease

Ebola Virus Disease (EVD) is among the most severe and life-threatening viral infections ever documented in human history. First discovered in 1976 near the Ebola River in the Democratic Republic of the Congo, it has since caused multiple outbreaks across Central and West Africa claiming thousands of lives and triggering global public health emergencies. What makes Ebola particularly alarming from a gastroenterology and internal medicine perspective is the way it attacks the body. The virus does not simply cause a fever and go away it launches a full-scale assault on the gastrointestinal system, the liver, and the vascular network simultaneously. Severe vomiting, profuse diarrhoea, abdominal pain, and catastrophic liver dysfunction are among its most defining and dangerous features.

For patients in Chennai whether they are managing existing liver conditions, digestive disorders, or planning international travel understanding Ebola Virus Disease is important. This comprehensive guide covers everything you need to know: what Ebola is, how it affects the gut and liver, what symptoms to watch for at every stage, how it spreads, how it is treated, and the steps you can take right now to protect yourself.

What is Ebola Virus Disease?

• Ebola Virus Disease is a severe, often fatal acute viral illness caused by infection with one of several species of the genus Ebolavirus. It belongs to the family Filoviridae a group of filamentous, enveloped RNA viruses and is classified under the broader medical category of viral haemorrhagic fevers (VHFs). This category includes other dangerous diseases such as Marburg virus disease, Lassa fever, and Crimean-Congo haemorrhagic fever.
• The disease was identified simultaneously in two locations in 1976: near the Ebola River in the Democratic Republic of the Congo and in what is now South Sudan. Both outbreaks were associated with high mortality, and the virus quickly became recognised as one of the most dangerous pathogens known to science.
• Ebola progresses with alarming speed. In the most serious cases, a patient can go from first symptoms to multi-organ failure within a matter of days. The virus overwhelms the immune system, destroys vascular integrity, and causes the kind of systemic shutdown that challenges even the most advanced intensive care units in the world.
• The largest Ebola outbreak in history the 2014–2016 West Africa epidemic resulted in more than 28,600 confirmed infections and over 11,300 deaths across Guinea, Liberia, and Sierra Leone. It demonstrated, vividly, what happens when a highly virulent haemorrhagic virus encounters communities without adequate healthcare infrastructure or containment capacity.

Key facts about Ebola Virus Disease:

• Fatality rates range from 25% to 90% depending on the strain and access to medical care
• Incubation period: 2 to 21 days from exposure to symptom onset
• The disease cannot spread from person to person before symptoms appear
• Six distinct species of Ebolavirus have been identified
• India has never recorded a confirmed case of EVD

Why Ebola is a Gastroenterology Concern

• This is a question worth addressing directly: why would a gastroenterologist write about Ebola?
• The answer lies in how profoundly the Ebola virus damages the gastrointestinal system and the liver two of the organ systems at the very core of gastroenterology practice.
• Within days of infection, EVD produces some of the most severe gastrointestinal symptoms of any known disease. Patients suffer from profuse, uncontrollable vomiting and watery diarrhoea sometimes losing more than 5 to 10 litres of fluid per day leading to catastrophic dehydration and electrolyte imbalances. Severe abdominal cramps, gut inflammation, and mucosal damage are common. The gastrointestinal tract essentially becomes a major battleground for the virus.
• At the same time, the liver becomes a primary target. Ebola virus directly infects and destroys hepatocytes (liver cells), causing massive hepatocellular necrosis. This leads to sharply elevated liver enzymes (AST, ALT), impaired synthesis of clotting factors which in turn causes the haemorrhagic complications EVD is known for and eventually acute liver failure in severe cases. The parallel to other severe liver conditions managed routinely in gastroenterology practice is striking.
• From a clinical perspective, the gastrointestinal presentation of early and intermediate Ebola infection can be difficult to distinguish from severe gastroenteritis, viral hepatitis, or acute cholangitis conditions managed daily in gastroenterology clinics. This makes clinical awareness among GI specialists particularly important.

The Six Species of Ebola Virus

Six species of the genus Ebolavirus are currently recognised. They differ in geographic origin, pathogenicity, and frequency of causing human outbreaks:

• Zaire ebolavirus (EBOV): The most prevalent and deadliest strain. Responsible for the majority of recorded outbreaks, including the catastrophic 2014–2016 West Africa epidemic. Case fatality rates can reach 90%. This is the strain for which FDA-approved treatments and vaccines exist.
• Sudan ebolavirus (SUDV): The second most common cause of human outbreaks. Case fatality rates range from 40% to 60%. Multiple outbreaks recorded in Uganda and South Sudan.
• Taï Forest ebolavirus (TAFV): Only a single documented human case a non-fatal infection in a scientist exposed to an infected chimpanzee in Côte d’Ivoire.
• Bundibugyo ebolavirus (BDBV): First identified in Bundibugyo district, Uganda, in 2007. Fatality rates of approximately 25–36%.
• Reston ebolavirus (RESTV): Can infect humans but has never been documented to cause clinical illness in people. Discovered in macaque monkeys exported from the Philippines to the USA.
• Bombali ebolavirus (BOMV): The most recently identified species, found in bats in Sierra Leone in 2018. Its human pathogenicity remains under study.

How Ebola Enters and Attacks the Body

• Understanding the biological mechanism of Ebola infection helps explain why the disease is so severe and why it creates such devastating gastrointestinal and hepatic complications.
• The Ebola virus enters the body through mucous membranes or breaks in the skin after direct contact with infected bodily fluids. Once inside, it targets and infects a range of cell types notably macrophages, monocytes, and dendritic cells which are key components of the immune system. Rather than triggering an effective immune response, these infected immune cells paradoxically become vehicles for spreading the virus throughout the body.
• The virus then spreads to regional lymph nodes, the liver, spleen, and adrenal glands. In the liver, it infects and kills hepatocytes at a massive scale, impairing the liver’s ability to produce clotting factors. In the adrenal glands, it disrupts cortisol production, contributing to the hypotension (low blood pressure) and shock seen in advanced EVD.
• As the infection progresses, the virus triggers a phenomenon sometimes called a “cytokine storm” a massive, dysregulated release of inflammatory molecules that damages blood vessel walls throughout the body. This increased vascular permeability allows fluid to leak out of blood vessels into surrounding tissues, contributes to severe diarrhoea, and eventually leads to the haemorrhagic features of advanced EVD. The gut wall itself becomes inflamed and permeable, compounding fluid loss.

Symptoms of Ebola Stage by Stage

Recognising Ebola’s symptoms at each stage is critical for prompt diagnosis and isolation. The average time from exposure to first symptoms is 8 to 10 days, though it can range from 2 to 21 days.

Stage 1: Early Phase (Days 1–3)

The earliest symptoms are non-specific and can mimic many common infections. This phase is often called the “dry phase” because overt fluid loss has not yet begun:

• Sudden onset of high fever typically above 38.6°C
• Severe headache, often described as the worst the patient has experienced
• Intense generalised muscle and joint pain (myalgia and arthralgia)
• Profound fatigue and weakness that sets in rapidly
• Sore throat
• Loss of appetite
• Chills and sweating

These symptoms alone are not enough to suspect Ebola without a relevant travel or exposure history.

Stage 2: Gastrointestinal Phase (Days 4–7)

This is the phase most relevant to gastroenterology and the most dramatic in its presentation. The gastrointestinal system becomes severely affected:

• Severe, persistent nausea and vomiting that may be virtually continuous
• Profuse, watery diarrhoea often described in outbreak reports as producing many litres of fluid per day, rapidly depleting the body’s reserves
• Intense abdominal cramps and diffuse abdominal pain
• Inflammation and mucosal damage along the gastrointestinal tract
• Dysphagia (difficulty swallowing) and painful throat
• Hiccups a characteristic and clinically notable feature of EVD, thought to relate to diaphragmatic irritation and gastrointestinal distension
• Conjunctival injection (red, inflamed eyes)
• A maculopapular rash, typically spreading from the trunk

The fluid and electrolyte losses during this phase are extreme. Without aggressive intravenous replacement therapy, patients can deteriorate into shock within days. This is why gastroenterologists and intensivists working together is so critical in EVD management.

Stage 3: Haemorrhagic and Multi Organ Failure Phase (Day 7 Onwards)

In severe cases, the disease progresses to its most feared stage the haemorrhagic phase:

• Bleeding from the eyes, ears, nose, gums, or rectum
• Blood in vomit (haematemesis) or stool (haematochezia/melaena) directly relevant to GI assessment
• Severe internal haemorrhage as clotting factor production from the damaged liver collapses
• Acute liver failure with jaundice in some patients
• Kidney failure with reduced or absent urine output
• Multi-organ dysfunction syndrome (MODS)
• Cardiovascular shock dangerously low blood pressure, tachycardia
• Neurological deterioration: confusion, seizures, coma
• Extreme cachexia and metabolic collapse

Patients who survive this stage face a long, difficult recovery and many experience what is now called Post-Ebola Syndrome, with ongoing symptoms including fatigue, joint pain, eye inflammation, and cognitive difficulties.

Ebola’s Impact on the Liver and Digestive System

Given Dr. Dinesh Ramaswamy’s area of expertise, it is worth exploring this dimension in greater clinical depth.

Hepatic Involvement in EVD:

The liver is one of the primary target organs of the Ebola virus. Multiple studies of outbreak patients have documented the following hepatic findings:

• Markedly elevated serum transaminases (AST and ALT) often 10 to 40 times the upper limit of normal
• Elevated bilirubin levels with clinical jaundice in severe cases
• Profound coagulopathy due to failure of hepatic synthesis of clotting factors (Factors V, VII, IX, X, and prothrombin)
• Histopathological evidence of extensive hepatocellular necrosis, Kupffer cell hyperplasia, and inflammatory infiltration in post-mortem studies
• Acute liver failure as a terminal event in the most severe cases

This hepatic picture bears similarities to other forms of acute viral hepatitis and acute liver failure conditions that gastroenterologists and hepatologists manage routinely. The key differentiating features are the haemorrhagic context, the travel and exposure history, and the coexisting severe gastrointestinal symptoms.

Gastrointestinal Mucosal Damage:

Beyond fluid loss, Ebola causes direct mucosal injury to the gastrointestinal lining. The virus infects endothelial cells and immune cells within the gut wall, causing inflammation, increased permeability, and mucosal breakdown. This explains why the diarrhoea in EVD can progress from watery to bloody a sign that mucosal integrity has been lost and the disease has entered its haemorrhagic phase.

Gastroenterologists evaluating patients with severe haemorrhagic diarrhoea and fever who have recently travelled to affected regions must have EVD in their differential diagnosis even if the presentation initially suggests infectious gastroenteritis or ischaemic colitis.

How does Ebola Spread?

Ebola does not spread through the air. This is the single most important fact for preventing unnecessary public panic. It is not transmitted by breathing near an infected person, coughing, or sneezing. It is also not spread by mosquitoes or any other insect vector.

Ebola spreads through direct contact with the bodily fluids of a person who is symptomatic with EVD or who has recently died from it. Infectious fluids include blood, vomit, diarrhoea, urine, saliva, sweat, tears, semen, vaginal secretions, and breast milk.

Primary routes of transmission:

• Direct contact with an infected person’s blood or body fluids through broken skin or mucous membranes
• Caring for an infected person without appropriate personal protective equipment (PPE)
• Participating in funeral or burial practices that involve touching the body of someone who died from EVD a historically significant source of transmission in affected communities
• Needlestick injuries or contact with contaminated medical instruments in healthcare settings
• Sexual contact the virus has been documented to persist in semen for up to 12 months or longer after a male survivor has otherwise fully recovered
• Handling or slaughtering wild animals particularly fruit bats and non-human primates in endemic regions
• Consuming bushmeat from affected areas

What does NOT transmit Ebola:

• Casual social contact sitting near, talking to, or shaking hands with someone (without fluid contact)
• Insect or mosquito bites
• Sharing food, water, or utensils in normal social circumstances
• Air, water, or soil
• Being in the same building or vehicle as an infected person without direct fluid contact

Who is at Risk?

For the overwhelming majority of people in Chennai, the risk of Ebola infection is effectively zero. However, specific groups have meaningfully elevated risk and should stay informed:

• International travellers to affected regions: Professionals, researchers, and tourists visiting Central or West Africa particularly during periods of active outbreak face the highest exposure risk.
• Healthcare workers: Doctors, nurses, surgeons, and paramedical staff who might assess or treat a patient with unrecognised EVD without adequate protective precautions.
• Gastroenterologists and GI endoscopists: Physicians performing procedures on patients with unexplained haemorrhagic gastroenteritis in the context of recent travel to affected areas should consider EVD in their differential and take appropriate precautions before any invasive procedure.
• Laboratory personnel: Staff handling blood and stool samples from febrile, recently travelled patients are at risk if samples are from an EVD-positive individual.
• Medical and humanitarian volunteers: Chennai-based healthcare workers volunteering in affected countries face occupational risk if infection prevention protocols are inadequate.
• Families and caregivers: Household members providing direct physical care to someone with EVD symptoms before diagnosis is established.

Diagnosis How is Ebola Detected?

Diagnosis of EVD requires a combination of clinical assessment, thorough exposure history, and laboratory confirmation.

Clinical assessment focuses on:

• Recent travel to a country or region with active or recent EVD outbreaks (within 21 days)
• Known or possible contact with a confirmed EVD patient
• Occupational exposure in a healthcare or laboratory setting
• Contact with wild animals or consumption of bushmeat in an endemic region

A patient presenting with sudden high fever, severe gastrointestinal symptoms (vomiting, profuse diarrhoea, abdominal pain), and relevant travel history should be isolated immediately and the relevant public health authorities notified before any confirmatory testing is performed.

Laboratory confirmation methods:

• RT-PCR (Reverse Transcription Polymerase Chain Reaction): The gold standard diagnostic test. Detects Ebola virus RNA in blood samples with high sensitivity and specificity. Results are typically available within hours at reference laboratories. Testing must be performed under Biosafety Level 4 (BSL-4) conditions.
• ELISA (Enzyme-Linked Immunosorbent Assay): Detects Ebola-specific antigens or antibodies. Useful in both the acute phase (antigen detection) and for serological surveys (antibody detection).
• Rapid Antigen Tests: Point-of-care rapid tests have been developed and deployed in outbreak settings for faster initial screening, though confirmation by RT-PCR remains required.
• Liver Function Tests and Coagulation Studies: While not diagnostic for Ebola specifically, dramatically elevated liver enzymes combined with a severe coagulopathy in a febrile patient with relevant travel history should intensify clinical suspicion significantly.
• In India, all confirmed or strongly suspected EVD testing is coordinated through the ICMR’s national reference laboratory network. State health authorities and the Union Ministry of Health must be immediately notified of any suspected case.

Treatment and Management of EVD

Managing Ebola Virus Disease requires a combination of antiviral treatment where available, intensive gastrointestinal and fluid management, organ support, and rigorous infection control.

Approved Antiviral Treatments

Inmazeb (atoltivimab, maftivimab, odesivimab-ebgn): Approved by the US FDA in October 2020, this three-antibody combination was the first specifically approved treatment for Zaire ebolavirus disease. It prevents viral entry into host cells by targeting the virus’s surface glycoprotein.

Ebanga (ansuvimab-zykl): A single monoclonal antibody approved by the FDA in December 2020. Works by blocking the virus from binding to cellular receptors. When administered early in the course of infection, both treatments significantly improve survival rates.

Gastrointestinal and Fluid Management Critical in EVD

This is where gastroenterology expertise becomes directly life-saving. The fluid losses in EVD are extraordinary. Patients require:

• Aggressive intravenous fluid resuscitation often several litres per day with careful electrolyte monitoring and correction
• Oral rehydration therapy when the patient can tolerate it, to supplement IV management
• Antiemetic medications to reduce vomiting and improve tolerability of oral intake
• Antidiarrhoeal supportive agents where appropriate
• Careful nutritional support enteral feeding (via nasogastric tube) when oral intake is impossible, progressing to normal feeding as tolerated
• Monitoring of liver function tests, coagulation studies, renal function, and blood counts daily

Haematological Support

Given the hepatic failure and coagulopathy central to EVD:

• Fresh frozen plasma and cryoprecipitate transfusions to replace clotting factors
• Platelet transfusions for thrombocytopaenia
• Packed red cell transfusions for anaemia from haemorrhage
• Vitamin K supplementation

Additional Supportive Measures

• Oxygen supplementation and ventilatory support as needed
• Vasopressors for haemodynamic shock
• Broad-spectrum antibiotics to manage secondary bacterial infections
• Antifungal agents for secondary fungal infections
• Management of acute kidney injury, including dialysis if needed
• Strict isolation with full PPE gown, double gloves, N95 respirator, face shield, and boot covers for all staff entering the patient’s room
• Meticulous psychological support for the patient and their family

Vaccination

The rVSV-ZEBOV vaccine (Ervebo) was approved by the FDA and EMA in 2019 and has demonstrated remarkable efficacy against Zaire ebolavirus in ring vaccination campaigns. A two-dose pre-exposure regimen Zabdeno (Ad26.ZEBOV) followed by Mvabea (MVA-BN-Filo) at 56-day intervals is approved for people at occupational or travel-related risk. Anyone planning to travel to an active outbreak zone should discuss vaccination with a travel medicine specialist well in advance.

Prevention Protecting Yourself and your Family

Since Ebola does not circulate naturally in India, prevention for people in Chennai is primarily about awareness, travel preparation, and knowing what to do if exposure occurs.

Before International Travel

• Check WHO and Indian Ministry of Health and Family Welfare travel advisories for your destination countries before travelling
• Consult Dr. Dinesh Ramaswamy’s clinic or a travel medicine specialist at least 4 to 6 weeks before departure to any high-risk region particularly if you have an underlying liver condition, gastrointestinal disorder, or compromised immunity, as these may affect your response to any potential infection
• Discuss pre-travel vaccination options including Ebola vaccination if your trip involves healthcare or field work in an endemic region
• Obtain and learn to correctly use personal protective equipment if your work involves clinical care or field research

During Travel in Affected Regions

• Avoid all direct contact with blood or bodily fluids of any person, especially those who are visibly unwell
• Do not touch or participate in preparing the bodies of those who have died, particularly in outbreak communities
• Avoid handling, slaughtering, or eating wild animals especially bats, monkeys, and apes in endemic regions
• Wash hands with soap and water frequently and thoroughly; use alcohol-based hand sanitiser with at least 60% alcohol concentration
• Eat only fully cooked food, drink only sealed bottled water, and avoid raw or undercooked animal products

After Returning to Chennai

• Monitor yourself daily for fever, vomiting, diarrhoea, abdominal pain, or unusual fatigue for 21 full days after returning from an affected region
• If any symptoms develop, call Dr. Dinesh Ramaswamy’s clinic or your nearest hospital before presenting in person do not use public transport
• Fully disclose your travel history to any doctor you see, even if you consider it unlikely to be relevant
• Follow all instructions from airport health officials regarding monitoring or quarantine

Liver and Gut Health Considerations

People with pre-existing liver disease including hepatitis B, hepatitis C, liver cirrhosis, fatty liver disease, or inflammatory bowel disease should be particularly cautious. The Ebola virus’s predilection for attacking the liver and gastrointestinal tract means that those with pre-existing conditions in these organ systems may be at greater risk of rapid deterioration if exposed. Discuss your specific risk profile with Dr. Dinesh Ramaswamy before any travel to high-risk regions.

When to See a Doctor

Time is the most important factor in EVD outcomes. Acting early but safely dramatically improves the chance of survival and limits the risk of onward transmission.

Call the clinic immediately before visitin if:

• You have been in a country with an active Ebola outbreak within the past 21 days AND you develop sudden fever (above 38°C), severe vomiting or diarrhoea, intense abdominal pain, unexplained bleeding, or extreme fatigue
• You are a healthcare worker who had an accidental needlestick or unprotected contact with a patient subsequently identified as having EVD
• You have had direct physical contact with someone confirmed to have EVD

Seek urgent gastroenterology evaluation if:

• You have returned from international travel and are experiencing severe, unexplained gastrointestinal bleeding (blood in vomit or stool) alongside fever
• You have signs of acute liver failure jaundice, confusion, abdominal swelling, abnormal bleeding following recent travel
• You are experiencing haemorrhagic diarrhoea that is not responding to standard treatment and you have a recent travel history

Contact Dr. Dinesh Ramaswamy’s Clinic:

• Phone: +91 96 7776 0926 | +91 755 817 1666 | 044-23626314
• Email: drdineshgis@gmail.com
• Hours: Monday to Saturday, 8:00 AM to 8:00 PM

Do not delay. If EVD is considered, early isolation and clinical evaluation are the most important steps — and they protect not just you but everyone around you.

Gastroenterology and Liver Care with Dr. Dinesh Ramaswamy, Chennai

Dr. Dinesh Ramaswamy is Chennai’s leading Gastroenterologist, Laparoscopic Surgeon, and GI Specialist, offering comprehensive diagnostic, therapeutic, and surgical care for the full spectrum of digestive and liver conditions.

His clinical expertise spans:

• Advanced Gastrointestinal Endoscopy: diagnostic and therapeutic upper GI endoscopy, colonoscopy, ERCP, and enteroscopy
• Hepatology and Liver Disease Management: viral hepatitis, alcoholic liver disease, fatty liver, liver cirrhosis, acute liver failure
• Complex GI Surgery: laparoscopic and robotic-assisted surgical procedures for colorectal, upper GI, pancreatic, and biliary conditions
• Inflammatory Bowel Disease (IBD): Crohn’s disease and ulcerative colitis
• Biliary and Pancreatic Disorders: gallstones, bile duct disease, pancreatitis, pancreatic cancer
• GI Oncology: colorectal cancer, gastric cancer, oesophageal cancer, liver and pancreatic tumours
• Travel-Related GI Illness Evaluation: for patients returning from international travel with unexplained gastrointestinal symptoms

For any concern related to liver health, gastrointestinal bleeding, severe vomiting or diarrhoea, unexplained abdominal pain, or complex digestive conditions including evaluation after international travel Dr. Dinesh Ramaswamy provides the highest level of specialist care backed by the latest technology and diagnostic capabilities.

Conclusion

Ebola Virus Disease is a complex, multisystem illness but its most immediate and life-threatening manifestations are gastrointestinal and hepatic. The severe diarrhoea, haemorrhagic vomiting, liver failure, and coagulopathy that define advanced EVD represent some of the most challenging clinical scenarios in medicine.

For Chennai residents, the practical risk today is very low. But awareness, preparedness, and knowing where to seek expert care make all the difference. If you have returned from travel with unexplained gastrointestinal symptoms, if you are managing a liver condition and planning international travel, or if you simply want expert guidance on digestive health Dr. Dinesh Ramaswamy is here to help. Your gut health and your liver deserve expert attention. Don’t wait until a symptom becomes a crisis.

Read more: Acid Reflux Diet Plan